The increased activation of kinases (PKR and PERK) that phosphorylate eIF2α and the decreased expression of phosphatase complex components that dephosphorylate eIF2α to terminate the ISR, such as PP1c and CREP, indicate that the ISR remains active in LSGs from SS patients. This evidence concerns the gene EIF2A and synovial sarcoma.